Calculate the Scoring Atopic Dermatitis (SCORAD) index to assess eczema severity. Evaluates extent, intensity, and subjective symptoms with treatment step recommendations.
The Scoring Atopic Dermatitis (SCORAD) index is the most widely used clinical tool for assessing the severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis, it combines three components: disease extent (percentage of body surface area affected), clinical intensity (six observable signs), and subjective symptoms (pruritus and sleep disturbance).
The SCORAD formula — A/5 + 7B/2 + C — weights intensity most heavily (maximum 63 points from the B component), reflecting the clinical importance of lesion severity. Scores range from 0 to 103, classified as mild (< 25), moderate (25–50), or severe (> 50). This three-category classification directly maps to treatment algorithms in international guidelines (EAACI, AAD, BAD).
In clinical practice, SCORAD is used for initial severity assessment, treatment step selection, disease monitoring over time, clinical trial endpoints, and insurance pre-authorization for biologic therapies. The Objective SCORAD (excluding subjective symptoms) is preferred in research settings where patient-reported outcomes may introduce variability.
Quantifying atopic dermatitis severity allows evidence-based treatment selection, objective monitoring of disease progression, and documentation for insurance coverage decisions. Without standardized scoring, treatment decisions rely on subjective impression, making it difficult to compare outcomes, justify therapy escalation, or participate in clinical trials. SCORAD provides a common language between dermatologists, primary care physicians, and patients.
SCORAD = A/5 + 7B/2 + C A = Extent (0–100% BSA) B = Intensity (6 items × 0–3 each = 0–18) C = Subjective symptoms (pruritus 0–10 + sleep loss 0–10 = 0–20) Max SCORAD = 100/5 + 7×18/2 + 20 = 20 + 63 + 20 = 103
Result: SCORAD = 24.0 (Mild), Objective SCORAD = 16.0
Extent (A) = 15% BSA, contributing 3.0 points. Intensity (B) = 4/18, contributing 14.0 points (the dominant component). Subjective (C) = 8/20, contributing 8.0 points. Total SCORAD = 3 + 14 + 8 = 25.0. This is at the mild-moderate boundary — regular emollients with topical corticosteroids for flares.
Use consistent units, verify assumptions, and document conversion standards for repeatable outcomes.
Most mistakes come from mixed standards, rounding too early, or misread labels. Recheck final values before use. ## Practical Notes
Use this for repeatability, keep assumptions explicit. ## Practical Notes
Track units and conversion paths before applying the result. ## Practical Notes
Use this note as a quick practical validation checkpoint. ## Practical Notes
Keep this guidance aligned to expected inputs. ## Practical Notes
Use as a sanity check against edge-case outputs. ## Practical Notes
Capture likely mistakes before publishing this value. ## Practical Notes
Document expected ranges when sharing results.
SCORAD includes subjective symptoms (pruritus, sleep loss) while EASI (Eczema Area and Severity Index) is entirely clinician-assessed. EASI is more commonly used in clinical trials; SCORAD is more common in clinical practice because it captures patient experience. Both are validated.
The Minimal Clinically Important Difference (MCID) for SCORAD is approximately 8.7 points. A decrease of this magnitude represents a meaningful improvement that patients and clinicians can perceive. For Objective SCORAD, the MCID is approximately 6.6 points.
The B component (intensity) can contribute up to 63 of the maximum 103 points because clinical lesion severity most directly impacts treatment decisions. A patient with 10% BSA involvement but severe oozing and excoriation needs more aggressive treatment than someone with 30% BSA of mild dryness.
Dryness is assessed on uninvolved (non-lesional) skin only, as involved skin may have multiple overlapping signs. Rate dryness 0-3 on typical unaffected skin: 0 = normal, 1 = slight roughness, 2 = rough with visible scaling, 3 = severe cracking.
Yes, but the visual analog scales (pruritus, sleep loss) can be challenging for young children. Parents can report on behalf of children under 7. For infants, clinician-assessed scores (Objective SCORAD) may be more reliable.
A SCORAD increase of > 8.7 points (the MCID) on current therapy suggests treatment failure. Persistent SCORAD ≥ 50 despite moderate-potency topical therapy or SCORAD ≥ 25 despite optimal topical management may warrant systemic therapy consideration.